



# PORTFOLIO

**WE DON'T DO INCREMENTAL.**

WE LIKE OUTLIERS.

THE BIG IDEAS THAT SHAKE THINGS UP.





ACQUIRED: NEUMORA,



ACQUIRED: NEUMORA,



ACQUIRED: MSFT,



, PUBLIC | CMPX



, PUBLIC | NASDAQ:DNLI



, PUBLIC | NASDAQ:EDIT



ACQUIRED: ILMN,



, ACQUIRED: BEAM,



, PUBLIC | NASDAQ:NMRA



ACQUIRED: PACB,



ACQUIRED: EXAS,



, PUBLIC | NASDAQ:TWST



, PUBLIC | NASDAQ:VERV



Digital Health



Digital Health



Medical Technology



Gene Editing



Proteomics



Digital Health

# CASE STUDY

## EDITAS MEDICINE

From Early-Stage Science to IPO

Editas Medicine is harnessing CRISPR-Cas9 gene editing to create genomic medicines for devastating and hard-to-treat diseases, including Usher syndrome and Duschenne muscular dystrophy.

Biomatics Capital's Dr. Boris Nikolic identified CRISPR as a very powerful game changing technology, after learning of the company through his academic and venture network.

In 2015, the partners of Biomatics played a key role in driving Editas to the next level of growth by leading a \$120 million Series B round, marking the largest financial investment to a CRISPR startup. Nikolic joined the board and took an active role in guiding the company to a \$94.4 million IPO, which was oversubscribed even in a difficult market.

▲ **Led \$120 million Series B in August 2015**

**Negotiated term sheet valuation**

**Joined board of directors**

**\$94.4 million oversubscribed IPO in February 2016**